不同基础输液与4种临床常用注射剂配伍前后不溶性微粒的测定分析  

Determination and analysis of the content of insoluble particles in different basic infusions before and after compatible with 4 commonly used clinical medications

作　　者：冯湘玲 李芸 陈娟[1] 丁玉峰 FENG Xiang-ling;LI Yun;CHEN Juan;DING Yu-feng(Department of Pharmacy,Tongji Hospital Affiliated with Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院药学部,湖北武汉430030

出　　处：《中国医院药学杂志》2020年第13期1438-1441,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:考察不同基础输液和4种临床常用注射剂配伍前后不溶性微粒的差异。方法:选取临床常用的3个厂家(内封式聚丙烯输液袋BFS、双层无菌软袋、直立式聚丙烯输液袋,编号厂家1、2、3)的0.9%氯化钠注射液(NS)和5%葡萄糖注射液(5%GS),测定不同基础输液与临床常用注射剂配伍前后2μm以上不溶性微粒数量。NS与注射用盐酸氨溴索配伍,5%GS与注射用地塞米松磷酸钠配伍。另外将多索茶碱注射液和奥拉西坦注射液分别与上述2种基础输液配伍。结果:空白输液中厂家1输液中不溶性微粒最少,厂家3最多。与注射剂配伍后,无论NS还是5%GS,厂家1输液中不溶性微粒最少,厂家3显著高于其他两家,尤其是2~5μm,5~10μm小粒径不溶性微粒。多索茶碱和奥拉西坦与同一厂家的5%GS和NS配伍后不溶性微粒数量相近,说明临床使用中与二者配伍皆宜。结论:不同基础输液与临床常用药配伍后不溶性微粒数量具有显著差异,提示生产企业应提高输液产品的质量控制标准,医院临床治疗需重视输液产品的遴选,为输液临床使用安全性提供保障。OBJECTIVE To investigate the difference of insoluble particles before and after compatibility of different basic infusions and four commonly used clinical injections.METHODS 0.9% sodium chloride injection(NS) and 5% glucose injection(5% GS) from 3 manufacturers(inner closed polypropylene infusion bag BFS, double sterile flexible bag, upright polypropylene infusion bag, No.: manufacturer 1, 2, 3) were selected to determine the number of insoluble particles more than 2 μm before and after compatibility of different basic infusions with commonly used clinical injections. NS was compatible with ambroxol hydrochloride for injection, and 5% GS was compatible with dexamethasone sodium phosphate for injection.In addition, doxofylline injection and oxiracetam injection were compatible with the above two basic infusions, respectively.RESULTS The number of insoluble particles in the blank infusion was the least in the infusion of manufacturer 1 and the most in the infusion of manufacturer 3.After compatibility with injections, manufacturer 1 had the least insoluble particles in the infusion irrespective of NS or 5% GS, and manufacturer 3 was significantly higher than the other two, especially the insoluble particles with small particle sizes of 2-5 μm and 5-10 μm. The number of insoluble particles was similar after compatibility of doxofylline and oxiracetam with 5% GS and NS from the same manufacturer, indicating that compatibility with both is appropriate in clinical use.CONCLUSION There are significant differences in the number of insoluble particles after compatibility of different basic infusions with common clinical drugs, suggesting that manufacturers should improve the quality control criteria of infusion products, and hospital clinical treatment should pay attention to the selection of infusion products to provide a guarantee for the safety of clinical use of infusions.

关 键 词：不溶性微粒 基础输液 光阻法 

分 类 号：R969[医药卫生—药理学]